Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Moore

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Drug Discovery & Development|May 17, 2005
Maximizing discovery efficiency with a computationally driven fragment approachWilliam R Moore
Bioorganic & Medicinal Chemistry Letters|April 30, 2014
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitorsStephen W Rafferty, Joel R Eisner, William R Moore, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2014
Design and optimization of highly-selective fungal CYP51 inhibitorsWilliam J Hoekstra, Edward P Garvey, William R Moore, et al.
Bioorganic & Medicinal Chemistry|January 9, 2003
Synthesis of 21,21-difluoro-3 beta-hydroxy-20-methylpregna-5,20-diene and 5,16,20-triene as potential inhibitors of steroid C17(20) lyasePhilip M Weintraub, Amy K Holland, Cynthia A Gates, et al.
ANZ Journal of Surgery|June 14, 2006
Early prosthetic complications after unipolar hemiarthroplastyPatrick C L Weinrauch, William R Moore, David R Shooter, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
The Journal of Clinical Investigation|May 3, 2017
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerJohn D Norris, Stephanie J Ellison, Jennifer G Baker, et al.
Journal of Medicinal Chemistry|December 4, 2010
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agentRupa S Shetty, Younghee Lee, Bin Liu, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Drug Discovery & Development|May 17, 2005
Maximizing discovery efficiency with a computationally driven fragment approachWilliam R Moore
Bioorganic & Medicinal Chemistry Letters|April 30, 2014
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitorsStephen W Rafferty, Joel R Eisner, William R Moore, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2014
Design and optimization of highly-selective fungal CYP51 inhibitorsWilliam J Hoekstra, Edward P Garvey, William R Moore, et al.
Bioorganic & Medicinal Chemistry|January 9, 2003
Synthesis of 21,21-difluoro-3 beta-hydroxy-20-methylpregna-5,20-diene and 5,16,20-triene as potential inhibitors of steroid C17(20) lyasePhilip M Weintraub, Amy K Holland, Cynthia A Gates, et al.
ANZ Journal of Surgery|June 14, 2006
Early prosthetic complications after unipolar hemiarthroplastyPatrick C L Weinrauch, William R Moore, David R Shooter, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
The Journal of Clinical Investigation|May 3, 2017
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancerJohn D Norris, Stephanie J Ellison, Jennifer G Baker, et al.
Journal of Medicinal Chemistry|December 4, 2010
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agentRupa S Shetty, Younghee Lee, Bin Liu, et al.
Pageof 1